Your browser doesn't support javascript.
loading
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis.
Borie, Raphael; Tabèze, Laure; Thabut, Gabriel; Nunes, Hilario; Cottin, Vincent; Marchand-Adam, Sylvain; Prevot, Grégoire; Tazi, Abdellatif; Cadranel, Jacques; Mal, Herve; Wemeau-Stervinou, Lidwine; Bergeron Lafaurie, Anne; Israel-Biet, Dominique; Picard, Clement; Reynaud Gaubert, Martine; Jouneau, Stephane; Naccache, Jean-Marc; Mankikian, Julie; Ménard, Christelle; Cordier, Jean-François; Valeyre, Dominique; Reocreux, Marion; Grandchamp, Bernard; Revy, Patrick; Kannengiesser, Caroline; Crestani, Bruno.
Afiliação
  • Borie R; APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Centre de compétence des maladies pulmonaires rares, Paris, France.
  • Tabèze L; INSERM, Unité 1152; Université Paris Diderot, Paris, France.
  • Thabut G; APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Centre de compétence des maladies pulmonaires rares, Paris, France.
  • Nunes H; INSERM, Unité 1152; Université Paris Diderot, Paris, France.
  • Cottin V; INSERM, Unité 1152; Université Paris Diderot, Paris, France.
  • Marchand-Adam S; Service de Pneumologie B, APHP, Hôpital Bichat, Paris, France.
  • Prevot G; APHP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France.
  • Tazi A; Service de Pneumologie, Centre national de référence des maladies pulmonaires rares, Hôpital Louis Pradel, Université Claude Bernard Lyon 1, Lyon, France.
  • Cadranel J; Service de Pneumologie, CHRU de Tours, Tours, France.
  • Mal H; Service de Pneumologie, Hôpital Larrey, Toulouse, France.
  • Wemeau-Stervinou L; APHP, Hôpital Saint-Louis, Service de Pneumologie, Paris, France.
  • Bergeron Lafaurie A; APHP, Service de Pneumologie, Centre de compétence des maladies pulmonaires rares, Hôpital Tenon, Paris, France.
  • Israel-Biet D; Service de Pneumologie B, APHP, Hôpital Bichat, Paris, France.
  • Picard C; Service de Pneumologie, Centre de compétence des maladies pulmonaires rares, CHRU de Lille, Lille, France.
  • Reynaud Gaubert M; APHP, Hôpital Saint-Louis, Service de Pneumologie, Paris, France.
  • Jouneau S; APHP, Hôpital Européen Georges Pompidou, Service de Pneumologie, Paris, France.
  • Naccache JM; Service de Pneumologie, Hôpital Foch, Suresnes, France.
  • Mankikian J; Service de Pneumologie, Hôpital Nord, Marseille, France.
  • Ménard C; Service de Pneumologie, Centre de compétence des maladies pulmonaires rares, Hôpital Pontchaillou; IRSET UMR 1085, université de Rennes 1, Rennes, France.
  • Cordier JF; APHP, Service de Pneumologie, Centre de compétence des maladies pulmonaires rares, Hôpital Tenon, Paris, France.
  • Valeyre D; Service de Pneumologie, CHRU de Tours, Tours, France.
  • Reocreux M; Departement de Génétique, APHP, Hôpital Bichat, Paris, France; Université Paris Diderot, Paris, France.
  • Grandchamp B; Service de Pneumologie, Centre national de référence des maladies pulmonaires rares, Hôpital Louis Pradel, Université Claude Bernard Lyon 1, Lyon, France.
  • Revy P; APHP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France.
  • Kannengiesser C; Departement de Génétique, APHP, Hôpital Bichat, Paris, France; Université Paris Diderot, Paris, France.
  • Crestani B; Departement de Génétique, APHP, Hôpital Bichat, Paris, France; Université Paris Diderot, Paris, France.
Eur Respir J ; 48(6): 1721-1731, 2016 12.
Article em En | MEDLINE | ID: mdl-27836952
ABSTRACT
Telomerase reverse transcriptase (TERT) or telomerase RNA (TERC) gene mutation is a major monogenic cause of pulmonary fibrosis. Sequencing of TERT/TERC genes is proposed to patients with familial pulmonary fibrosis. Little is known about the possible predictors of this mutation and its impact on prognosis.We retrospectively analysed all the genetic diagnoses made between 2007-2014 in patients with pulmonary fibrosis. We evaluated the prevalence of TERT/TERC disease-associated variant (DAV), factors associated with a DAV, and the impact of the DAV on survival.237 patients with pulmonary fibrosis (153 with familial pulmonary fibrosis, 84 with telomere syndrome features without familial pulmonary fibrosis) were tested for TERT/TERC DAV. DAV was diagnosed in 40 patients (16.8%), including five with non-idiopathic interstitial pneumonia. Prevalence of TERT/TERC DAV did not significantly differ between patients with familial pulmonary fibrosis or with only telomere syndrome features (18.2% versus 16.4%). Young age, red blood cell macrocytosis, and low platelet count were associated with the presence of DAV; the probability of DAV was increased for patients 40-60 years. Transplant-free survival was lower with than without TERT/TERC DAV (4.2 versus 7.2 years; p=0.046).TERT/TERC DAV were associated with specific clinical and biological features and reduced transplant-free survival.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA / Telômero / Telomerase / Fibrose Pulmonar Idiopática Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA / Telômero / Telomerase / Fibrose Pulmonar Idiopática Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article